BioStock: Coegin Pharma aims high in 2022

In 2021, Coegin Pharma reached a key milestone by launching a combined phase I/II clinical trial with AVX001 in actinic keratosis patients. Moreover, the company expanded its pipeline in order to pursue cancer indications and chronic kidney disease. BioStock reached out to Coegin’s CEO Tore Duvold to hear what he had to say about the company’s achievements during 2021 and his goals for 2022.

Read the interview with Tore Duvold at biostock.se:

https://www.biostock.se/en/2022/01/coegin-pharma-aims-high-in-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/